Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy of daptomycin treatment versus vancomycin
treatment in the treatment of methicillin resistant staphylococcus aureus (MRSA) bloodstream
infections (BSI) due to isolates with high vancomycin minimum inhibitory concentrations (MIC)
(i.e. > or equal to 1.5 ug/ml) in terms of reducing all-cause mortality.
Our secondary aim is to compare clinical failure rates of daptomycin treatment versus
vancomycin treatment and to compare time to microbiological clearance in patients treated
with daptomycin versus those treated with vancomycin.
Our primary hypothesis is that Daptomycin treatment is superior to vancomycin treatment in
reducing mortality from BSIs due to MRSA with high vancomycin MIC from 25% to 10%.